D
Daniel J. Lenihan
Researcher at Vanderbilt University Medical Center
Publications - 166
Citations - 9052
Daniel J. Lenihan is an academic researcher from Vanderbilt University Medical Center. The author has contributed to research in topics: Heart failure & Cancer. The author has an hindex of 32, co-authored 140 publications receiving 6193 citations. Previous affiliations of Daniel J. Lenihan include Vanderbilt University.
Papers
More filters
Journal ArticleDOI
Contrast Induced Nephropathy after Angiography
Journal ArticleDOI
Cardio-Oncology: Time to Get More Mechanistic
Javid Moslehi,Daniel J. Lenihan +1 more
TL;DR: In this article, the authors proposed a method to improve the accuracy of the analysis of the data collected from the data acquisition process, and the results of the experiment were analyzed.Corresponding Authors
JournalDOI
Report on the international colloquium on cardio-oncology (rome, 12-14 march 2014).
Michael S. Ewer,Luca Gianni,Fabrizio Pane,Maria Teresa Sandri,Rudolf Steiner,Leszek Wojnowski,Edward T.H. Yeh,Joseph R. Carver,Steven E. Lipshultz,Giorgio Minotti,Gregory T. Armstrong,Daniela Cardinale,Steven D. Colan,Sarah C. Darby,Thomas Force,Leontien C. M. Kremer,Daniel J. Lenihan,Stephen E. Sallan,Douglas B. Sawyer,Thomas M. Suter,Sandra M. Swain,Flora E. van Leeuwen +21 more
TL;DR: The colloquium programme looked at patients as the authors see them in their fight against cancer and eventually returning to everyday life, and represents the melting pot in which anti-cancer therapies, genetic backgrounds, and risk factors conspire in producing cardiovascular sequelae.
Journal ArticleDOI
Elevated Cardiovascular Disease Risk in Patients With Chronic Myelogenous Leukemia Seen in Community-based Oncology Practices in the United States
Anna D. Coutinho,Dinara Makenbaeva,Eileen Farrelly,Pamela Landsman-Blumberg,Daniel J. Lenihan +4 more
TL;DR: The increased risk of CVD observed in this real‐world analysis of patients with CML underscores the importance of current National Comprehensive Cancer Network recommendations to consider cardiovascular risk when selecting tyrosine kinase inhibitors.
Journal ArticleDOI
An International Survey of Health Care Providers Involved in the Management of Cancer Patients Exposed to Cardiotoxic Therapy
Jeffrey Sulpher,Shrey Mathur,Daniel J. Lenihan,Chris A. Johnson,Michele Turek,Angeline Law,Ellamae Stadnick,Franco Dattilo,Nadine Graham,Susan Dent +9 more
TL;DR: There continues to be a lack of consensus on the definition of cardiotoxicity and a discrepancy in clinical practice between cardiologists and oncologists, and differences in opinion require resolution through more effective research collaboration and formulation of evidence-based guidelines.